GlassScriptPhysician profile
Hayah Kassis-George
NPI 1508182411
$49,881.56
in general payments reported to CMS, 2019-2025
26 companies · $27K in 2025
The $27K reported for 2025 was more than what 97% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,223 · 2020: $2,322 · 2021: $284 · 2022: $5,374 · 2023: $481 · 2024: $12K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Honoraria: $10K · Food and Beverage: $2,800 · Travel and Lodging: $1,018 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,390.00 |
| Honoraria | $10,400.00 |
| Food and Beverage | $2,800.35 |
| Travel and Lodging | $1,017.93 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $22,236.80 | 2024-2025 | |
| United Therapeutics Corporation | $16,438.29 | 2019-2025 | Remodulin, Orenitram, Tyvaso |
| Merck Sharp & Dohme LLC | $4,442.56 | 2022-2025 | Winrevair, Verquvo |
| Novartis Pharmaceuticals Corporation | $1,761.05 | 2019-2024 | |
| Abbott Laboratories | $1,536.92 | 2019-2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Actelion Pharmaceuticals US, INC. | $674.47 | 2019-2025 | Uptravi, Opsumit |
| Astrazeneca Pharmaceuticals LP | $569.37 | 2019-2025 | Farxiga, Wainua |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $417.67 | 2019-2024 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $389.18 | 2019-2024 | |
| Vifor Pharma, INC. | $257.05 | 2019-2020 | |
| Amgen INC. | $189.96 | 2019-2023 | Repatha |
| Pfizer INC. | $139.02 | 2019-2024 | |
| Kiniksa Pharmaceuticals, LTD. | $128.18 | 2022-2023 | Arcalyst |
| Abiomed | $102.69 | 2024-2025 | Impella |
| Liquidia Technologies, INC. | $101.23 | 2025 | Yutrepia |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.74 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $100.34 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $82.56 | 2019-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $45.54 | 2023 | Watchman Access System |
| Impulse Dynamics (USA) INC. | $40.80 | 2022-2024 | Optimizer |
| Gilead Sciences, INC. | $36.74 | 2019 | |
| Medtronic, INC. | $31.98 | 2024 | Corevalve Evolut R |
| Becton, Dickinson and Company | $24.03 | 2025 | Hemosphere |
| Mannkind Corporation | $18.19 | 2025 | |
| Sandoz INC. | $16.20 | 2025 | Treprostinil |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hayah Kassis-George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.